Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tonglin Guben formula is a Traditional Chinese Medicine (TCM) herbal prescription developed by The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. It is primarily indicated for the treatment of renal calculi and the clearance of residual clinically insignificant renal fragments (CIRF) following flexible ureteroscopic lithotripsy (FURL). The formula is designed to promote the expulsion of small stone fragments (typically ≤4 mm) through diuretic and potentially litholytic effects, while also addressing underlying renal health according to TCM principles. It has been evaluated in clinical trials both as a monotherapy and in combination with standard alkalizing agents like potassium sodium hydrogen citrate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tonglin Guben formula.